Cell‐type Selective Phototoxicity Achieved with Chlorophyll‐a Derived Photosensitizers in a Co‐culture System of Primary Human Tumor and Normal Lung Cells

The ATP‐dependent transporter ABCG2 exports certain photosensitizers (PS) from cells, implying that the enhanced expression of ABCG2 by cancer cells may confer resistance to photodynamic therapy (PDT) mediated by those PS. In 35 patient‐derived primary cultures of lung epithelial and stromal cells, PS with different subcellular localization and affinity for ABCG2 displayed cell‐type specific retention both independent and dependent on ABCG2. In the majority of cases, the ABCG2 substrate 2‐[1‐hexyloxyethyl]‐2‐devinyl pyropheophorbide‐a (HPPH) was lost from fibroblastic cells more rapidly than from their epithelial counterparts, even in the absence of detectable ABCG2 expression, facilitating selective eradication by PDT of epithelial over fibroblastic cells in tumor/stroma co‐cultures. Pairwise comparison of normal and transformed epithelial cells also identified tumor cells with elevated or reduced retention of HPPH, depending on ABCG2. Enhanced ABCG2 expression led to the selective PDT survival of tumor cells in tumor/stroma co‐cultures. This survival pattern was reversible through HPPH derivatives that are not ABCG2 substrates or the ABCG2 inhibitor imatinib mesylate. PS retention, not differences in subcellular distribution or cell signaling responses, was determining cell type selective death by PDT. These data suggest that up‐front knowledge of tumor characteristics, specifically ABCG2 status, could be helpful in individualized PDT treatment design.

[1]  F. Guillemin,et al.  Recent improvements in the use of synthetic peptides for a selective photodynamic therapy. , 2006, Anti-cancer agents in medicinal chemistry.

[2]  David Kessel,et al.  Photodynamic therapy of cancer: An update , 2011, CA: a cancer journal for clinicians.

[3]  Hailong Wu,et al.  Expression of ABCG2 (BCRP) Is Regulated by Nrf2 in Cancer Cells That Confers Side Population and Chemoresistance Phenotype , 2010, Molecular Cancer Therapeutics.

[4]  A. Kozubík,et al.  Drug efflux transporters, MRP1 and BCRP, affect the outcome of hypericin-mediated photodynamic therapy in HT-29 adenocarcinoma cells , 2009, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

[5]  R. Pandey,et al.  Substrate affinity of photosensitizers derived from chlorophyll-a: the ABCG2 transporter affects the phototoxic response of side population stem cell-like cancer cells to photodynamic therapy. , 2010, Molecular pharmaceutics.

[6]  S. Bates,et al.  ABCG2-mediated transport of photosensitizers: Potential impact on photodynamic therapy , 2005, Cancer biology & therapy.

[7]  R. Jain,et al.  Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[8]  W. Gallagher,et al.  Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy , 2009, Photochemistry and photobiology.

[9]  S. Nakahara,et al.  Biological modulation by lectins and their ligands in tumor progression and metastasis. , 2008, Anti-cancer agents in medicinal chemistry.

[10]  Micheline Piquette-Miller,et al.  Regulation of drug transporters during infection and inflammation. , 2007, Molecular interventions.

[11]  F. Guillemin,et al.  Improvement of meta-tetra(hydroxyphenyl)chlorin-like photosensitizer selectivity with folate-based targeted delivery. synthesis and in vivo delivery studies. , 2008, Journal of medicinal chemistry.

[12]  A. Yoshimura,et al.  Increased expression of the LGALS3 (Galectin 3) gene in human non–small‐cell lung cancer , 2003, Genes, chromosomes & cancer.

[13]  Konstantinos N. Halkiotis,et al.  In vitro evaluation of the genotoxic and clastogenic potential of photodynamic therapy. , 1999, Mutagenesis.

[14]  M. Calin,et al.  Photodynamic therapy in oncology , 2006 .

[15]  H. Pass,et al.  Sensitivity of different human lung cancer histologies to photodynamic therapy. , 1990, Cancer research.

[16]  Heinz Baumann,et al.  Cross-Linking of Signal Transducer and Activator of Transcription 3—A Molecular Marker for the Photodynamic Reaction in Cells and Tumors , 2007, Clinical Cancer Research.

[17]  C. Decaestecker,et al.  Galectin‐3 Upregulation During Tumor Progression in Head and Neck Cancer , 2008, The Laryngoscope.

[18]  Hideki Mori,et al.  Neural stem/progenitor cells damaged by reactive oxygen species evolved in photosensitizing reaction , 2011, Neuroscience Letters.

[19]  Heinz Baumann,et al.  Photodynamic Therapy Causes Cross-linking of Signal Transducer and Activator of Transcription Proteins and Attenuation of Interleukin-6 Cytokine Responsiveness in Epithelial Cells , 2004, Cancer Research.

[20]  R. Boyle,et al.  Structure and Biodistribution Relationships of Photodynamic Sensitizers * , 1996, Photochemistry and photobiology.

[21]  M. E. Kenney,et al.  Structural Factors and Mechanisms Underlying the Improved Photodynamic Cell Killing with Silicon Phthalocyanine Photosensitizers Directed to Lysosomes Versus Mitochondria , 2009, Photochemistry and photobiology.

[22]  Patrizia Agostinis,et al.  Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. , 2007, Biochimica et biophysica acta.

[23]  Chao Liu,et al.  In vitro cellular uptake and dimerization of signal transducer and activator of transcription-3 (STAT3) identify the photosensitizing and imaging-potential of isomeric photosensitizers derived from chlorophyll-a and bacteriochlorophyll-a. , 2011, Journal of medicinal chemistry.

[24]  T. Ishikawa,et al.  Functional Validation of the Genetic Polymorphisms of Human ATP-Binding Cassette (ABC) Transporter ABCG2: Identification of Alleles That Are Defective in Porphyrin Transport , 2006, Molecular Pharmacology.

[25]  A. Johansson,et al.  Tumor Selectivity at Short Times Following Systemic Administration of a Liposomal Temoporfin Formulation in a Murine Tumor Model , 2007, Photochemistry and photobiology.

[26]  J. Frasor,et al.  Proinflammatory Cytokines Enhance Estrogen-dependent Expression of the Multidrug Transporter Gene ABCG2 through Estrogen Receptor and NFκB Cooperativity at Adjacent Response Elements*♦ , 2010, The Journal of Biological Chemistry.

[27]  Ekat Kritikou Stem cells: Introducing the next generation , 2007, Nature Reviews Molecular Cell Biology.

[28]  H. Zankl,et al.  In vitro evaluation of the cytotoxic and mutagenic potential of the 5-aminolevulinic acid hexylester-mediated photodynamic therapy. , 2004, Mutation research.

[29]  P. Acedo,et al.  Mitotic catastrophe induced in HeLa cells by photodynamic treatment with Zn(II)-phthalocyanine. , 2008, International journal of oncology.

[30]  G. Murphy The ADAMs: signalling scissors in the tumour microenvironment , 2008, Nature Reviews Cancer.

[31]  S. Rose-John,et al.  Interleukin-31 and Oncostatin-M Mediate Distinct Signaling Reactions and Response Patterns in Lung Epithelial Cells* , 2007, Journal of Biological Chemistry.

[32]  Daniel B. Shin,et al.  Photofrin Uptake in the Tumor and Normal Tissues of Patients Receiving Intraperitoneal Photodynamic Therapy , 2006, Clinical Cancer Research.

[33]  G. Kéri,et al.  High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. , 2004, Molecular pharmacology.

[34]  J. Schuetz,et al.  Role of ABCG2/BCRP in biology and medicine. , 2006, Annual review of pharmacology and toxicology.

[35]  M. McNiven,et al.  Dynamin 2 mediates fluid-phase micropinocytosis in epithelial cells , 2007, Journal of Cell Science.

[36]  Satyajit Mayor,et al.  Pathways of clathrin-independent endocytosis , 2007, Nature Reviews Molecular Cell Biology.

[37]  J. Behravan,et al.  Interleukin-1 beta and tumor necrosis factor-alpha increase ABCG2 expression in MCF-7 breast carcinoma cell line and its mitoxantrone-resistant derivative, MCF-7/MX , 2009, Inflammation Research.

[38]  Janet Morgan,et al.  The Tyrosine Kinase Inhibitor Imatinib Mesylate Enhances the Efficacy of Photodynamic Therapy by Inhibiting ABCG2 , 2007, Clinical Cancer Research.

[39]  Frédéric Blanchard,et al.  Transformation of human bronchial epithelial cells alters responsiveness to inflammatory cytokines , 2005, BMC Cancer.

[40]  B. Henderson,et al.  Conjugation of 2-(1'-hexyloxyethyl)-2-devinylpyropheophorbide-a (HPPH) to carbohydrates changes its subcellular distribution and enhances photodynamic activity in vivo. , 2009, Journal of medicinal chemistry.

[41]  K. Sakakura,et al.  Expansion and characterization of cancer stem-like cells in squamous cell carcinoma of the head and neck. , 2009, Oral oncology.

[42]  T. Ishikawa,et al.  Key Role of Human ABC Transporter ABCG2 in Photodynamic Therapy and Photodynamic Diagnosis , 2010, Advances in pharmacological sciences.

[43]  F. S. Pardo,et al.  Imatinib-mediated inactivation of Akt regulates ABCG2 function in head and neck squamous cell carcinoma. , 2008, Archives of otolaryngology--head & neck surgery.

[44]  Nancy L Oleinick,et al.  The role of apoptosis in response to photodynamic therapy: what, where, why, and how , 2002, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

[45]  T. Kiesslich,et al.  Cellular mechanisms and prospective applications of hypericin in photodynamic therapy. , 2006, Current medicinal chemistry.

[46]  J. Usuda,et al.  Breast cancer resistant protein (BCRP) is a molecular determinant of the outcome of photodynamic therapy (PDT) for centrally located early lung cancer. , 2010, Lung cancer.

[47]  Robert W. Robey,et al.  Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells , 2009, Cancer Chemotherapy and Pharmacology.

[48]  Michael Dean,et al.  The livestock photosensitizer, phytoporphyrin (phylloerythrin), is a substrate of the ATP-binding cassette transporter ABCG2. , 2006, Research in veterinary science.

[49]  Mukund Seshadri,et al.  Light Delivery over Extended Time Periods Enhances the Effectiveness of Photodynamic Therapy , 2008, Clinical Cancer Research.